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ABSTRACT
Venous thromboembolism (VTE) remains among the leading causes of maternal mortality in the developed world, presenting 
variably as deep vein thrombosis (DVT), pulmonary embolism (PE) or cerebral vein thrombosis (CVT), among others. Obesity 
in particular has been recognized as the principal contributing factor to the risk of VTE in pregnancy and with the global 
increase in the rates of obesity affecting reproductive age women, heightened awareness of the risk and consequences 
of VTE in this population are vital. Thus, prophylaxis, diagnosis and treatment of VTE in the obese gravida are discussed. 
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INTRODUCTION
Venous thromboembolism (VTE) is a major cause of 
mortality in pregnant women in the developed world [1, 
2], often presenting as deep vein thrombosis (DVT) or pul-
monary embolism (PE), and more rarely as cerebral vein 
thrombosis (CVT). Obesity is a well-known risk factor for 
these potentially fatal complications, and has been linked 
with a higher likelihood of maternal death in the United 
Kingdom’s Confidential Enquiries into Maternal Deaths and 
Morbidity [2]. Given the paucity of randomized-controlled 
trials in this field, most recommendations come from ob-
servational studies and expert opinion. With the increase in 
the rates of obesity in women of reproductive age in Poland, 
focused guidance is needed to support both parturients 
and practitioners throughout pregnancy and postnatally. 
As such, the current review, focuses on the role of obesity 
as a leading risk factor for VTE, and readers are directed to 
other published works for discussion of other VTE-related 
risk factors, including thrombophilia and history of prior 
events [3–5].
EPIDEMIOLOGY
The actual incidence of VTE in pregnancy is difficult to 
estimate, owing to its relative rarity, retrospective observa-
tions, variable risk factor profiles and inconsistent thrombo-
prophylaxis. A reasonable and accepted incidence is about 
1–2/1000 pregnancies [6]. A large-scale Scandinavian study 
conducted between 2001 and 2011, assessing the risk of 
VTE during 180 days postpartum, showed a cumulative in-
cidence of 18.4/10,000 deliveries, compared to 4.7/10,000 in 
non-pregnant women; with the highest risk in the first week 
postpartum [7]. On the other hand, the absolute risk of 
antepartum VTE was recently estimated at 8–9/10,000 de-
liveries [8]. This finding is consistent with the literature, with 
estimates of the risk of VTE of 6 to 9 times higher during 
the third trimester, 84 fold higher in the first 2–6 weeks 
postpartum, and up to 60 fold higher in the first 3 months 
postpartum, as compared to the non-pregnant popula-
tion [8]. This corresponds to the maternal pregnancy-relat-
ed physiologic alterations of hemostatic parameters, with 
the peak of the pro-coagulant state in the third trimester 
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and early postpartum period, potentiated by the inherent 
vascular damage sustained at time of delivery. Yet, while 
the VTE risk predominates during these time periods, the 
magnitude of risk in the first and second trimesters should 
not be underestimated [9], and may be heightened by the 
pro-coagulant states associated with early stages of preg-
nancy, such as hyperemesis gravidarum or ovarian hyper-
stimulation syndrome [10].
Obesity stands among the most frequent risk factors for 
VTE in the obstetric population, augmenting the risk aris-
ing from the pregnancy and puerperium themselves, with 
an adjusted odds ratio (OR) of 5.3 (95% confidence interval 
[CI] 2.1–13.5) [6]. Similarly, a BMI of 25–29.9 kg/m2 (over-
weight) is considered a weaker, yet common risk factor for 
VTE [10]. Furthermore, an obese parturient is at a greater risk 
of a PE (adjusted OR 14.9, 95% CI 3.0–74.8) than DVT (ad-
justed OR 4.4, 95% CI 1.6–11.9) [11], the significance of which 
becomes apparent with the observation that 60% of women 
who died from PE in the UK between 2003 and 2008 were 
obese (body mass index [BMI] 30 kg/m2 or higher), and al-
most every woman who died from VTE after vaginal delivery 
was obese and/or over 40 years old [10]. 
With Poland noted in 2014 to have one of the highest 
rates of obesity amongst countries within the European Un-
ion, with the contribution of overweight women 18 years or 
older cited at 46.7% [12], a comprehensive understanding 
of the prophylaxis, diagnosis, and management of VTE is 
paramount. 
PATHOGENESIS OF VTE
The Virchow’s triad (comprised of venous stasis, hyper-
coagulable blood, and vascular damage) as the inciting 
mechanism for development of VTE has been long-recog-
nized [13]. The expected, physiologic alterations typical of 
pregnancy have the potential to affect all three of these 
elements. Venous stasis intensifies with advancing gesta-
tion through progesterone-mediated venodilation, venous 
compression of the pelvic veins by the gravid uterus and 
structurally-driven compression of the left iliac vein by the 
right iliac artery, at its crossover point [14]. This latter obser-
vation clarifies the predilection of VTE formation in the left 
lower extremity [15, 16]. Additionally, a shift within the he-
mostatic parameters favouring hypercoagulability, induced 
in anticipation of peripartum blood loss; emulated by the 
increase of pro-coagulant factors (fibrinogen and factors V, 
IX, X and VIII), decrease in anticoagulant activity (diminished 
protein S and elevated activated protein C resistance) and 
reduction in fibrinolytic activity (increased plasminogen 
activator inhibitor type 1 and 2 and decreased tissue plasmi-
nogen activator), results in intensified thrombin generation 
and tempered clot dissolution [13]. The risk for VTE induced 
by the procoagulant state is further augmented in individu-
als diagnosed with thrombophilia [17]. Finally, this risk is 
potentiated by the vascular disruption of pelvic vasculature 
sustained during vaginal delivery, and to a greater extent 
during operative delivery or Cesarean section [13]. 
Beyond these physiologic alterations, the domains of the 
Virchow’s triad are further affected by obesity. The additional 
abdominal adiposity and persistently elevated intra-ab-
dominal pressure further restrict venous return above the 
effects already exerted by the weight of the gravid uterus 
[15]. Challenges with ambulation and altered mobility may 
result in relative inactivity, further hindering venous return 
and potentiating VTE risk [15]. 
Finally, the high metabolic activity of adipose tissue, 
resulting in the liberation of substances including interleu-
kin-6, plasminogen activator inhibitor-1 and tumor necrosis 
factor-α (TNF-α), tissue factor, and (PAI-1), generates 
a hypofibrinolytic, prothrombotic, proinflammatory, envi-
ronment, heightens endothelial dysfunction and promotes 
oxidative stress. This cascade in turn further exacerbates the 
risk of a VTE [18–20].
PREVENTION OF VTE  
IN OBESE PREGNANT WOMEN
Based on existing practice guidelines pharmacologic 
thromboprophylaxis is suggested once the estimated VTE 
risk is thought to surpass 1% [16]. Whereas antenatal throm-
boprophylaxis is not indicated solely for high BMI, the po-
tentiation of risk in the presence of co-existing risk factors 
predisposing to VTE cannot be underestimated (Table  1) 
[10, 16, 21]. 
For patients with clinical or laboratory suspicion of an in-
creased bleeding risk, the benefits and hazards of bleeding 
and thrombosis must be considered and management deci-
sions should be made following discussion with the treating 
haematologist, with acquired expertise in the treatment of 
such disorders in pregnancy. Proposed prophylactic doses of 
low molecular weight heparin (LMWH) according to weight 
are presented in Table 2.
CLINICAL MANIFESTATIONS OF VTE
Heightened attentiveness to the signs and symptoms of 
VTE is crucial for prompt assessment and treatment and in 
order to decrease the risk of mortality [22]. Yet this intent is 
frustrated by the similarities between the classic symptoms 
of VTE (notably edema of the affected extremity, tachycardia, 
tachypnea, and dyspnea), and common symptoms frequent-
ly disclosed during the course of uncomplicated pregnancy, 
but often more frequently reported by the obese pregnant 
patient, sometimes leading to diagnostic delays [22–24].
Unilateral leg pain and swelling (especially of the left 
lower extremity) are more indicative of DVT, particularly if 
associated with local discomfort and warmth, or a degree 
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of leukocytosis beyond what would be expected for preg-
nancy alone [22, 25]. Additional relevant elements, such 
as immobilization, unequal calf-size differing by > 3 cm 
(measured 10 cm below the tibial tuberosity), or unilateral 
swelling affecting the entire extremity warrant in-depth 
assessment [26]. Similarly, less typical presentation consist-
ing of abdominal discomfort, or reports of pain solely in 
the flank, buttocks, or groin are suspicious in women with 
an increased risk of VTE and clarification of their etiology 
should be pursued, as they may be indicative on an iliac vein 
thrombosis, the risk of which is increased in pregnancy [27]. 
PE most commonly presents with dyspnea and pleu-
ritic chest pain, although it can also be associated with 
cough, hematemesis, or syncope [26, 28]. Although more 
rarely, increased jugular venous pressure and cardiovascular 
collapse have also been documented [26]. These symp-
toms may be seen in absence of or in association with the 
symptoms of DVT [26]. Barring absolute contraindications, 
Table 1. Risk assessment for VTE prophylaxis (RCOG) [10]
Risk factor Score
Pre-existing risk factors
Previous VTE except a single event related to major surgery 4
Previous VTE provoked by major surgery 3
Known high-risk thrombophilia 3
Medical comorbidities, e.g. cancer, heart failure; active systemic lupus erythematosus, inflammatory polyarthropathy or 
inflammatory bowel disease; nephrotic syndrome; type I diabetes mellitus with nephropathy; sickle cell disease; current 
intravenous drug use not user
3
Family history of unprovoked or estrogen-related VTE in first-degree relative 1
Known low-risk thrombophilia (no VTE) 1
III degree obesity — BMI = 40 or more 2
II degree obesity — BMI = 30 or more 1
Gross varicose veins 1
Parity ≥ 3 1
Smoker 1
Age > 35 years 1
Obstetric risk factors
Pre-eclampsia in current pregnancy 1
ART/IVF (antenatal only) 1
Multiple pregnancy 1
Caesarean section in labour 2
Elective caesarean section 1
Mid-cavity or rotational operative delivery 1
Prolonged labour (> 24 hours) 1
PPH (> 1 litre or transfusion) 1
Preterm birth < 37 weeks in current pregnancy 1
Stillbirth in current pregnancy 1
Transient risk factors
Any surgical procedure in pregnancy or puerperium except immediate repair of the perineum, e.g. appendicectomy, postpartum 
sterilisation 3
Hyperemesis 3
OHSS (first trimester only) 4




≥ 4 antenatally, consider thromboprophylaxis from the first trimester
3 antenatally, consider thromboprophylaxis from 28 week
≥ 2 postnatally, consider thromboprophylaxis for at least 10 days
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if required investigations cannot be completed expedi-
tiously, weight-based, therapeutic anticoagulation ought 
to be commenced pending test completion [14].
Diagnostic modalities
The routine approach to VTE assessment requires modi-
fication in pregnancy, given that existing prediction rules 
have been extrapolated from studies on non-pregnant in-
dividuals and have not undergone validation in pregnancy 
[14, 16]. Existing guidelines discourage their use or the sole 
dependence on negative d-dimer results to rule out VTE in 
pregnancy [16], and encourage objective investigations 
including imaging.
Deep vein thrombosis
Compression ultrasound (CUS) of the venous system 
is the principal imaging modality for investigation of DVT 
during pregnancy, as it is non-invasive and allows for avoid-
ance of radiation exposure [27, 29]. Targeted examination 
extending from the iliac vein to the popliteal vein, incor-
porating Doppler interrogation of iliac vein flow (normally 
non-compressible) is crucial in view of the risk of iliac vein 
DVT in pregnancy [16, 22, 24, 30]. Whereas a negative CUS 
has a negative predictive value of 98.9% (95% CI 95.5–99.8) 
during pregnancy and postpartum, a repeat CUS within 
one-week is suggested by most current guidelines [16, 29]. 
Where obstruction of the iliac vein is suspected by the ab-
sence of flow, an MRI may be indicated to further clarify the 
diagnosis [16].
Pulmonary embolism (PE)
In individuals presenting with respiratory symptoms 
suggestive of a PE, investigation for a DVT is still warranted 
[16, 27, 31]. Should a DVT be identified, weight-based thera-
peutic anticoagulation is required as for a PE, thus further 
imaging for a PE may be unnecessary, avoiding its inherent 
radiation exposure [27, 31]. Should DVT imaging be nega-
tive or unavailable, a ventilation/perfusion (V/Q) scan or 
computer tomographic pulmonary angiography (CT-PA) is 
indicated for the diagnosis of PE [16, 31]. While the reported 
fetal radiation dose associated with a CT-PA is 0.01 milliGray 
(mGy), the fetal radiation dose associated with the perfusion 
part of the V/Q scan is 0.12 mGy; correlating with projections 
of fatal malignancy to 15 years of age of < 1/1,000,000 and 
1/280,000, respectively [32]. Whereas this may render the 
CT-PA a better modality form the fetal perspective, it should 
be noted that the degree of fetal radiation for both CT-PA 
and the perfusion portion of the V/Q scan are well below the 
safety thresholds, lack teratogenic associations, and reflect 
extremely low absolute risks [33]. Conversely, CT-PA delivers 
10 mGy of radiation to the maternal breast in contrast to 
the perfusion part of a V/Q scan which delivers 0.28 mGy; 
a dose 40 times higher at a sensitive time of rapid breast 
tissue proliferation, potentially increasing the lifetime risk 
of breast cancer [27, 31]. 
Cerebral vein thrombosis
The incidence of cerebral vein thrombosis (CVT) is much 
lower than DVT and PE, and has been reported to occur in 
0.01–0.04% of pregnancies [16]. BMI > 30 kg/m2 increases 
the risk of CVT (adjusted OR 3.50; 95% CI 2.00–6.14), while 
hormonal contraception exacerbates this risk further (ad-
justed OR 29.26; 95% CI 13.47–63.60) [34]. Pregnancy, the 
third trimester and postpartum period in particular, has also 
been associated with an increased risk of CVT [35]. Typical 
symptoms consist of generalized, progressively worsening 
headache, and at times “thunderclap” headache [36]. This 
may be accompanied by diplopia and papilledema, owing 
to sixth nerve palsy [35]. Convulsions, abnormal mentation, 
and focal deficits may also be present [37]. It is important 
to appreciate that CT without contrast will often be normal 
inspite of a CVT [35]. Time-of-flight magnetic resonance ve-
nography (TOF MRV) is the preferred imaging technique for 
diagnosis, especially antenatally [38]. Following diagnosis, 
therapeutic anticoagulation, detailed below, as for any form 
of VTE should be commenced [16].
Table 2. Weight-based dosing of LMWH 
Indication Weight [kg]
Agent (administered subcutaneously)
Enoxaparin [mg] Dalteparin [units] Nadroparin [units]
Prophylactic
< 50 20 mg daily 2,500 units daily 1,900 units daily
50–90 40 mg daily 5,000 units daily 2,850 units daily (< 70 kg)3,800 units daily (> 70 kg)
91–130 60 mg daily 7,500 units daily 38 units/kg daily
131–170 80 mg daily 10,000 units daily 38 units/kg daily
> 170 0.6 mg/kg 75 units/kg daily 38 units/kg daily
Therapeutic 1 mg/kg bid or1.5 mg/kg daily
200 units/kg daily or 
100 units/kg bid 86 units/kg bid
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MANAGEMENT OF ACUTE VTE
Choice of treatment agent
LMWH is the preferred agent for treatment of VTE dur-
ing pregnancy, whereas unfractionated heparin (UFH) is 
an alternate choice should LMWH be unavailable or con-
traindicated [16, 21, 31, 39]. Both LMWH and UFH potenti-
ate the activity of antithrombin (including anti-factor-IIa 
and anti-factor-Xa activity), reduce formation of thrombus, 
and enhance fibrinolysis [14]. Neither agent crosses the 
placenta [40, 41]. A recent systematic review substantiated 
the safety and efficacy of LMWH for management of VTE in 
pregnancy, focusing on the reduced likelihood of bleeding, 
osteoporosis, and heparin-induced thrombocytopenia (HIT) 
in comparison to UFH [42–44]. No instances of HIT have 
been documented thus far with use of LMWH in pregnancy; 
nevertheless, it is worth mentioning that in cases of HIT 
or allergies to UFH/LMWH, heparanoids (i.e. fondaparinux 
or danaparoid), agents that lack cross-reactivity with HIT 
antibodies, may be considered during pregnancy following 
hematologic consultation [42, 45, 46].
Vitamin K antagonists, such as warfarin, cross the pla-
centa and are typically not indicated for management of 
VTE in pregnancy except in very unique circumstances, as 
they are associated with substantial fetal risks consisting of 
teratogenicity, fetal demise, and fetal hemorrhage [16, 21, 
47–49]. Novel anticoagulation agents, such as oral direct 
thrombin inhibitors (i.e. dabigatran) and anti-Xa inhibitors 
(i.e. rivaroxaban, apixaban) are also to be avoided, given 
absence of pregnancy data [16, 21, 39]. 
Finally, thrombolytic therapy (streptokinase, r-tPA, uroki-
nase) should be considered carefully, given its associated 
risk of hemorrhagic complications, and only in instances of 
massive VTE associated with hemodynamic compromise 
or with a potential threat to life or limb [16, 31, 39, 50, 51]. 
The use of vena cava filters should likewise be restricted to 
cases of acute VTE in the setting of imminent or threatened 
labour with contraindication to anticoagulation, or where 
substantial bleeding is encountered [16, 52–54].
Anticoagulation dosage, duration,  
and peripartum management
Dosing of therapeutic LMWH is weight-based (Table 2). 
Pregnancy-related physiologic adaptation resulting in am-
plification of maternal blood volume peaking in the third 
trimester at around 50%, augmentation of glomerular fil-
tration with higher renal excretion, and enhancement of 
protein-binding, alter the pharmacokinetic properties of 
LMWH and UFH [55]. Twice-daily dosing for maintenance of 
therapeutic levels has been proposed by some [16, 31], while 
once-daily dosing is supported by others [55]. Similarly, the 
need for anti-FXa monitoring remains unclear [9, 16, 31].
All women receiving LWMH antenatally should be ad-
vised to withhold injections when bleeding is noticed or 
labour begins [10]. Prophylactic anticoagulation can be 
ceased with labour onset, or if delivery is planned, the last 
dose should be administered the day before the planned 
date [15, 16, 31]. Planned delivery is recommended for 
women on therapeutic anticoagulation [15, 16]. In cases of 
VTE diagnosis within 2–4 weeks preceding delivery, bridging 
with intravenous UFH should be considered during labour, 
to limit the length of time without anticoagulation [16, 39]. 
Placement of neuraxial anesthesia is safe 4 hours after IV 
UFH is stopped, when aPTT normalizes; 12 hours following 
a prophylactic dose of LMWH; or 24 hours after a therapeutic 
dose of LMWH [56]. 
Re-initiation of LMWH can typically be accomplished 
safely 4–6 hours after vaginal delivery or 6–12 hours after 
Caesarean section, but at least 4 hours after removal of the 
epidural catheter [21, 56]. Respecting these time-frames, 
one approach is to give a prophylactic dose of LMWH once 
hemostasis is satisfactory, followed by resumption of the 
therapeutic dose 24 hours later, as indicated [16]. 
All women with BMI 40 kg/m2 or greater should be con-
sidered for prophylactic dose of LMWH in weight-adjusted 
doses for 10 days after delivery, regardless of mode of deliv-
ery (vaginal, elective or emergency Caesarean section) [6]. 
When BMI = 30 kg/m2 or more, but less than 40 kg/m2, addi-
tional risk factors must be taken into consideration (Table 1) 
when deciding on postpartum thromboprophylaxis. An-
ticoagulation in the setting of an acute VTE diagnosed in 
pregnancy should continue for the duration of pregnancy 
and for at least 6 weeks postpartum; for a total duration of 
at least three months [12, 19, 29]. LMWH and warfarin can be 
used in the postpartum period, as both are compatible with 
breastfeeding [12, 19, 29].
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